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Opinion statement
Management of non-small cell lung cancer (NSCLC) with brain metastasis (BrM) has been
revolutionized by identification of molecular subsets that have targetable oncogenes.
Historically, survival for NSCLC with symptomatic BrM was weeks to months. Now, many
patients are surviving years with limited data to guide treatment decisions. Tumors with
activating mutations in epidermal growth factor receptor (EGFRact+) have a higher
incidence of BrM, but a longer overall survival. The high response rate of both systemic
and BrM EGFRact+ NSCLC to tyrosine kinase inhibitors (TKIs) has led to the rapid incorpo-
ration of new therapies but is outpacing evidence-based decisions for BrM in NSCLC. While
whole brain radiation therapy (WBRT) was the foundation of management of BrM,
extended survival raises concerns for the subacute and late effects radiotherapy. We favor
the use of TKIs and delaying the use of WBRT when able. At inevitable disease progression,
we consider alternative dosing schedules to increase CNS penetration (such as pulse
dosing of erlotinib) or advance to next generation TKI if available. We utilize local control
options of surgery or stereotactic radiosurgery (SRS) for symptomatic accessible lesions
based on size and edema. At progression despite available TKIs, we use pemetrexed-based
platinum doublet chemotherapy or immunotherapy if the tumor has high expression of
PDL-1. We reserve the use of WBRT for patients with more than 10 BrM and progression
despite TKI and conventional chemotherapy, if performance status is appropriate.
Introduction
Metastatic lung cancer remains a devastating diagnosis,
due in part to the high incidence of brain involvement;
however, advances in targeted therapy are prolonging
survival [1••]. Lung cancer with brain metastasis (BrM)
remains an incurable disease and the goals of care are
optimizing quality of life (QOL) and maximizing dura-
tion of disease control. Unfortunately, given the toxicity
of many treatments, the presence of neurologic symp-
toms limited the therapies that could be offered to
patients. However, the availability of more tolerable
and effective agents is changing the historical approach
to BrM.
The treatment of non-small cell lung cancer
(NSCLC), which accounts for 85% of lung cancer diag-
nosis, is being transformed by the identification of on-
cogenic driver mutations [2•]. Mutations are present in
60% of adenocarcinomas and the current standard of
care is to evaluate molecular markers, particularly muta-
tions in epidermal growth factor receptors (EGFR), in
advanced disease. There is expanding evidence that these
are unique tumors in regard to prognosis, incidence of
metastases, and treatment response. While lower inci-
dence, there are other clinically applicable driver muta-
tions that have targeted therapies, including ALK, ROS-1,
BRAF, MEF, and RET-1, that will not be addressed in this
paper as it is uncommon for patients to express more
than one driver mutation [3].
The feedback loop from bench to bedside has per-
haps never been as productive as with EGFR in NSCLC.
High expression of EGFR has been recognized in multi-
ple malignancies with significant expression in lung
cancer with BrM [4, 5]. Small molecules, tyrosine kinase
inhibitors (TKIs) were developed to target these recep-
tors. A subpopulation of Asian, female, non-smokers
with adenocarcinoma had a striking sustained response
rate (RR). Evaluation of EGFR genotype in the highly
responsive subpopulation lead to identification of mul-
tiple mutations in the activating domain of EGFR
(EGFRact+). These mutations have higher affinity for
first generation TKIs than wildtype EGFR (EGFRwt) [6,
7]. With increased screening for EGFRact+ in NSCLC, it
is clear that the phenotype of Asian, non-smoking wom-
en with adenocarcinoma only accounts for about 60%
of patients. Overall frequency of EGFRact+ in Europe is
15% and 22% in North America [8•]. Up to 25%
patients with EGFRact+ NSCLC are current smokers
[9]. NSCLC expressing EGFRact+ are distinct with a
higher incidence of BrM, greater overall survival and
possibly increased response to radiotherapy [10].Within
the EGFRact+ mutations, retrospective studies have also
suggested that specific mutationsmay be both predictive
and prognostic marker for better outcome [11].
Despite changes in the treatment of systemic NSCLC,
recommendations for management of BrM are based on
mixed populations of solid tumors. While there is lim-
ited evidence to support whole brain radiation (WBRT)
compared to best supportive care, it has been the foun-
dation ofmanagement in patients withmultiple BrM for
many decades. Given advancements in systemic therapy
as well as radiosurgery (SRS), the late cognitive effects
associated with WBRT is of increasing significance on
QOL [12•]. Additionally, the tolerability of TKIs enables
these agents to be offered to most patients regardless of
performance status, expanding the populations eligible
for subsequent local therapy.
There remain multiple unanswered questions in the
management of BrM in EGFRact+ NSCLC. This paper
reflects our current practice based on the evidence avail-
able. The development of new therapies and ongoing
clinical trials examining the combination of local and
systemic therapies will continue to transform the man-
agement of BrM in EGFRact+NSCLC in the coming years.
Systemic therapy
Traditionally, systemic therapy had a limited role in the management of BrM,
largely due to limitations in blood-brain barrier (BBB) permeability as well as
the risk of toxicity to surrounding healthy brain tissue. Advances in conven-
tional chemotherapy as well as TKIs are changing the management of BrM. TKIs
are first line therapy for advanced systemic EGFRact+ NSCLC and given toler-
ability and rapid action of these agents, we offer these medications to all
 22 Page 2 of 16 Curr. Treat. Options in Oncol.  (2017) 18:22 
EGFRact+ NSCLC patients regardless of performance status. We carefully mon-
itor for CNS response and progressionwithMRIs. In our experience, response to
these agents enables subsequent therapies that would not otherwise be tolerat-
ed. Platinum doublet chemotherapy utilizing pemetrexed is reserved for disease
refractory to TKIs. We typically reserve immunotherapy until progression de-
spite conventional chemotherapy, unless there is high tumor expression of
PDL-1. We utilize bevacizumab (BEV) for the management of steroid refractory
cerebral edema as well as radiation necrosis; recognizing it may also have an
oncolytic effect.
EGFR tyrosine kinase inhibitors
Consideration of current use of EGFR TKIs requires greater understanding of
their brief and transformative history. When initially studied, TKIs had less than
20% RR in an unselected population. Subsequent evaluation of tumor
genomics lead to the identification of driver mutations in EGFR (EGFRact+)
[6, 7]. Driver mutations are genetic alterations found within a tumor that result
in constitutively active forms of signaling proteins and lead to sustained tumor-
genesis. The most common EGFR activating mutations are deletions of exon 19
(exon19del) and pointmutations of exon 21 (L858R) [13]. On exon 20, T790M
is a resistance mutation that is seen in TKI naïve patients and in 60% of patients
who develop resistance to TKIs [14]. This has led to a third generation of TKIs
specifically targeting T790M. While there is data to support lower rates of CNS
progression in EGFRact+ NSCLC treated with TKI compared to conventional
chemotherapy, the brain is a frequent site of disease recurrence after an initial
response to TKIs [15, 16]. Currently available agents were not designed for BBB
penetration; however, there are multiple agents in the pipeline designed for
increased CNS penetration.
The use of TKIs in patients with BrM is expanding without randomized trials
to guide treatment strategies (Table 1). As withmost early clinical trials, patients
with active BrM were largely excluded from the initial trials of TKIs. The
currently available studies are limited in that they are small and predominately
single arm or retrospective studies with variable evaluation for EGFRact+. While
CNS concentrations of all currently available agents are lower than plasma, CNS
disease in EGFRact+ patients have high RR to TKIs. There are ongoing clinical
trials to specifically evaluate the use of these agents in patients with BrM and
active CNS disease as well as evaluations of new agents designed specifically for
increased BBB penetration.
First and second generation TKIs
Gefitinib, a first generation TKI, has CSF concentration approximately 1% of
serum; however, the concentration may increase with WBRT [17, 18]. The first
prospective trial of gefitinib in NSCLCwith BrMwas conducted in Italy and had
a low RR; however, they did find that patients who had previously received
WBRT, had better disease control compared to radiation naïve patients [19]. As
with all early studies, patients were not molecularly selected for EGFRact+ and
gefitinib did not demonstrate a survival benefit [20]. While not molecularly
selected, studies conducted in Asian countries enrolling predominately adeno-
carcinoma had high RR (60% in a Japanese study that had prior radiotherapy
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and 81% in a Chinese study treated in combination with WBRT) [21, 22].
Subsequent studies in EGFRact+ patients have demonstrated a RR of 87.8% as
monotherapy with overall survival (OS) 21.9 months [23••]. Gefitinib is the
most common first line TKI in Asian countries and retrospective studies of
EGFRact+ enriched populations have supported the use of TKIs asmonotherapy
without radiation [24, 25•, 26].
Erlotinib is a first generation TKI that is more commonly used in the USA
due in part to sustained FDA approval and increased CSF penetration (approx-
imately 5% of serum in patients with BrM which is above the minimum
inhibitory concentration) [27–29]. Early prospective trials failed to demonstrate
a survival benefit with the addition of erlotinib to radiotherapy in patients with
BrM; however, these trials did not screen for EGFRact+ [30–32, 33•]. A subse-
quent study with a small percentage of patients evaluated for EGFRact+ con-
firmed CNS response varied by genotype; EGFRwt patients survived
11.8months; however, OS in EGFRact+ patients was 19.1months [34]. Current
dosing of erlotinib at 150 mg daily is based on inhibition of EGFRwt; however,
mathematical modeling suggested pulse dosing strategy could delay develop-
ment of resistance and CNS progression in EGFRact+ [35]. In 2011,








Afatinib [41] Post hoc
phase 3
37% prior XRT All EGFRact+ 91 19.78 m
Erlotinib [32] Phase I 21% prior CT + XRT WBRT NS 11 4.4 m
Erlotinib [103] Phase 2 Prior CT 8/23
EGFRact+
48 18.9 m
Erlotinib [48] Phase 2 Prior TKI + XRT 6/7
EGFRact+
7 2.9 m
Erlotinib [33•] Phase 2 Prior CT WBRT 1/35
EGFRact+
80 3.4 m
Erlotinib [104] Phase 2 Prior CT or CT + XRT WBRT 11/23
EGFRact+
23 10.7 m
Erlotinib [34] Phase 2,
multiI





Erlotinib [82] Phase 3 WBRT + SRS NS 126 6.1 m
Gefitinib [23••] Phase 2 Prior CT All EGFRact+ 41 21.9 m
Gefitinib [105] Phase 2 Prior CT or CT + XRT Palliative care Chinese NS 40 14 m
Gefitinib [22] Phase 2 Prior CT WBRT Chinese NS 21 13 m
Gefitinib [19] Phase 2 90% prior CT, 44%
prior XRT
NS 41 5 m
Gefitinib [20] Phase 2 Prior CT WBRT NS 59 6.3 m
Icotinib [37•] Phase I 25% prior CT WBRT All EGFRact+ 15 20.8 m
Icotinib [38] Phase 2 80% prior CT WBRT 10/18
EGFRact+
20 22 m
CT chemotherapy, EGFRact+ epidermal growth factor activating mutation,mmonths,MultiImulti-institutional, NS not screened for EGFRact+, OS
overall survival, SRS radiosurgery, TKI tyrosine kinase inhibitor, WBRT whole brain radiation therapy, XRT radiotherapy
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retrospective case series of patients treated with weekly high-dose erlotinib
supported a partial CNS response in six of nine patients [36]. Recently, an
open-label study of 34 patients treated with a pulse of high-dose erlotinib for
2 days a week and otherwise 50 mg daily [37•]. While this did not prevent the
development of T790M resistance, all patients with BrM had intracranial re-
sponse and no patients with disease progression developed new BrM [37•]. This
dosing strategy still needs to be studied in a randomized trial; however, it
provides an additional treatment option for those patients with isolated intra-
cranial disease progression. When considering dosing of erlotinib, it is also
important to note that smoking decreases the bioavailability of erlotinib [9].
Icotinib, another first-generation TKI, is approved for use in China and has
CSF concentration approximately 1% of serum that fluctuates with radiother-
apy [38]. Dose escalation studies in combination with WBRT have confirmed
safety and RR of 80% in a small phase II of 20 patients (at least 50% with
EGFRact+) [39]. There are multiple ongoing trials further examining this agent
in combination with radiotherapy for BrM (NCT01926171, NCT02726568,
NCT01724801).
Afatinib, a second generation TKI, is unique as an irreversible inhibitor of
EGFRact+, EGFRwt, Erb-2, and Erb-4. Likely secondary to its effects on EGFRwt,
this agent is associated with greater toxicity; however, dose reduction in the first
6 months due to adverse events was not associated with decreased in
progression-free survival (PFS) [40]. Subgroup analysis of LUX-Lung 3 and 6
confirmed CNS activity of this agent and superiority to conventional chemo-
therapy with increased intracranial PFS if patients had priorWBRT [41]. There is
also a case study of five patients who declined WBRT and had complete
intracranial response to afatinib [42].
While trials directly comparing first generation TKIs with BrM are ongoing
(NCT2714010), retrospective analysis does not support significant survival
difference between erlotinib and gefitinib [43–45]. LUX-Lung 7, a prospective
comparison of afatinib to gefitinib did support improved time to treatment
failure for the use of afatinib over gefitinib; however, there was no difference for
15% patients with asymptomatic BrM [46].
At the time of progression, there is a lack of prospective data to support
transitioning between first and second generation TKIs. Current guidelines
recommend re-biopsy or cell-free DNA testing at clinically significant disease
progression to evaluate for T790M resistance which would guide transitioning
to a third-generation TKI. The LUX-Lung 4 study prospectively evaluated tran-
sitioning to afatinib in patients progressing on a first-generation TKI and found
a response rate of only 8.2%; however, this study excluded patients with active
CNS disease [47]. There are reports of intracranial response to erlotinib after
progressing on gefitinib [23••, 44, 48] and afatinib [49]. But, there are also
retrospective studies of patients with active CNS disease, both of brain metas-
tases and leptomeningeal disease, who progressed on prior treatments with
erlotinib or gefitinib but had intracranial response to afatinib [50]. Additional-
ly, there have been reports of patients responding to erlotinib even after devel-
opment of the T790M [51, 52]. We utilized pulse dosing for isolated CNS
progression, as there is evidence that T790M mutations are less common in
BrM during pharmacokinetic failure than in systemic disease [51]. At systemic
disease progression with identification of T790M resistance mutation, we tran-
sition to third-generation TKIs.
Curr. Treat. Options in Oncol.  (2017) 18:22 Page 5 of 16  22 
Third-generation TKIs
In 60% of cases, the development of resistance to a first- or second-
generation TKI is due to the acquired point mutation T790M. This muta-
tion is in the ATP binding pocket and prevents inhibition by first- and
second-generations TKIs. Osimertinib is a potent irreversible inhibitor of
T790M that demonstrated a response rate of over 60% in patients with
T790M in early trials leading to the breakthrough designation. Supporting
use of osimertinib over conventional chemotherapy, the AURA3 trial dem-
onstrated an impressive PFS of 10.1 months for osimertinib compared to
4.4 months for pemetrexed containing platinum doublet chemotherapy
[53••]. This PFS benefit was true even for the over 30% of patients with
asymptomatic BrM at enrollment with a hazard ratio of 0.32 [53••].
Intracranial response has also been reported in patients with BrM as well
as patients with leptomeningeal disease [54–56]. For patients with T790M,
either primary or secondary, we favor the use of osimertinib for the use of
EGFRact+ BrM.
Future agents
There are multiple TKIs in early clinical phases that are focusing on
increased CNS penetration [57•]. One example, the ongoing phase I study
of AZD3759, reported preliminary data that 11 of 21 patients had intra-
cranial response [58]. Other ongoing clinical trials of new TKIs in NSCLC
with BrM including tesevatinib (NCT02616393) and ASP 8273
(NCT02113813).
Platinum doublet chemotherapy
Conventional chemotherapy was thought to have a limited role in the
treatment of BrM due to concerns about BBB penetration. While not
equal to serum, pemetrexed, an antifolate chemotherapy, has CSF con-
centration only 2% lower than plasma [59]. Systemic RR are similar or
lower than intracranial RR in a phase II trials with delayed or concurrent
WBRT [60, 61]. Additionally, retrospective analysis found lower rate of
symptomatic BrM in NSCLC patients treated with pemetrexed either in
first or second line therapy [62]. For patients with advanced adenocar-
cinoma NSCLC with non-operable asymptomatic BrM, pemetrexed had
similar intracranial and extracranial response of 80 and 70%, respective-
ly [63]. While there was limited inclusion of patients with BrM in the
large phase III trials, pemetrexed maintenance was shown to improve
survival [64]. Based on data from IMPRESS trial, continuing TKI with
conventional chemotherapy is not recommended [65]. There are multi-
ple phase III trials to evaluate dose of pemetrexed and use in combina-
tion with radiotherapy and TKIs (NCT02284490, NCT02162537,
NCT01951469). In patients with non-squamous NSCLC who do not
respond to TKIs or at recurrence after osimertinib, platinum doublet
chemotherapy of pemetrexed with carboplatin for four to six cycles is
recommended for patients with performance status of 0–2. After com-
pletion of six cycles, or if side effects prevent further cycles, we utilize
pemetrexed as maintenance therapy.
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Immunotherapy
The three immune checkpoint inhibitors approved for use in NSCLC,
nivolumab, pembrolizumab, and atezolizumab, have also revolutionized
the treatment of NSCLC [66]. Preclinical work supports T cell exhaustion
and decreased PDL-1 expression on EGFRact+ tumors [67]. Given the high
RR of EGFRact+ tumors to TKIs, clinical trials of checkpoint inhibitors have
excluded EGFRact+ patients, as well as patients with active CNS disease.
Given these limitations, the use of immunotherapy in EGFRact+ NSCLC
with BrM is limited to case series and small trials that have demonstrated
efficacy [68••], although also with significant neurologic side effects [69].
There are ongoing trials combining immunotherapy with TKIs in EGFRact+
NSCLC (NCT02085070). At this time, checkpoint inhibitors are reserved
for use after TKIs and usually not until progression on conventional
chemotherapy unless there is high expression of PDL-1.
Antiangiogenic therapy
Bevacizumab (BEV) has demonstrated a survival benefit in combination
with platinum doublet chemotherapy in non-squamous NSCLC, al-
though these trials excluded patients with known CNS metastasis given
concerns for intracranial hemorrhage [70]. Subsequently, the safety of
the addition of BEV in patients with non-squamous NSCLC BrM, even
in the setting of full anticoagulation, has been demonstrated [71•]. For
this reason, addition of BEV to platinum doublet chemotherapy is
recommended in non-squamous NSCLC. While it excluded patients with
BrM, an open-label phase II study comparing the addition of BEV to
erlotinib in first line therapy demonstrated a PFS benefit compared to
erlotinib alone; survival data has not matured and a phase III study is
ongoing [72]. At this time, the use of BEV in treatment of BrM is
primarily in the management of steroid refractory vasogenic edema
and for the management of radiation necrosis with recognition that
there may be a benefit to tumor control as well.
Local therapy
Surgery
The survival and QOL benefits of surgery for treatment of a single symp-
tomatic BrM are based on randomized trials from the 1990s with a
population of primarily lung cancer patients. These trials were randomized
to surgical resection and WBRT or WBRT alone and found not only a
survival benefit to the surgical group, but also benefit in functionally
independent survival [73, 74]. While a more recent retrospective study of
patients with BrM at initial diagnosis of NSCLC did not demonstrate a
survival benefit to surgery, surgery did improve QOL when presenting with
neurologic symptoms [75]. Advances in neurosurgical techniques allow
access to more lesions with low surgical complications and morbidity of
only 1.8% at high volume centers [76]. Given the response of BrM to
radiotherapy and systemic therapies, we reserve surgery for large (greater
than 3 cm), symptomatic, accessible BrM or if additional histologic diag-
nosis is required.
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Radiotherapy
Radiotherapy has been the foundation of treatment of solid tumor BrM for
decades; however, the type and timing of radiotherapy remains highly variable
in clinical practice. Given EGFRact+ is a positive prognostic factor with high RR to
TKIs, we typically reserve the use of radiotherapy until after TKI response can be
evaluated. The clinical evidence to support this decision is limited to multiple
small studies of TKIs or conventional chemotherapy as monotherapy (Table 2).
These studies have supported the use of systemic therapies to delay radiation
therapy from 12.6 to 17.9 months [25•, 48, 77••]. A recently reported retrospec-
tive study suggests increased survival with combination of up-front SRS and TKI
compared to salvage strategy [78••]. Review of this literature provides a founda-
tion for our practice of delayingWBRT to evaluate for response to systemic agents.
Whole brain radiation therapy
Due to limited CNS penetration of older systemic therapies, WBRT, with or
without surgery, was the cornerstone of management of BrM, based on evidence
that patients were less likely to die of neurologic causes despite a lack of survival
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NR NR 1) 40.8 m
2) 20.5 m
CT chemotherapy, EGFRact+ epidermal growth factor activating mutation, m months, iPFS intracranial progression free survival, iRR intracranial
response rate, NM data not matured, NS not screened for EGFRact+, NR not reported, PFS progression free survival, ORR overall response rate, OS
overall survival, RR response rate, TKI tyrosine kinase inhibitor, XRT radiotherapy
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benefit [79]. Multiple studies evaluating the safety of chemotherapy in conjunc-
tion with WBRT demonstrated improved CNS control; however, there was no
improvement in OS. No survival benefit has been demonstrated when compar-
ing early WBRT to delayed following conventional chemotherapy [80]. Small
studies examining the use of TKIs and WBRT have provided conflicting results
and it remains unclear if addition of TKI to radiotherapy improved survival [81]
or could possibly have deleterious effects [82]. In contrast, clinical trials have
reported that patients were limited in receiving subsequent systemic treatment
due to deteriorations in performance status after WBRT [26]. Meta-analysis also
confirms more side effects with radiotherapy compared to TKIs alone [83•].
The benefits of radiation therapy must be weighed with not only the short-
term side effects, but given survival of years for many patients with EGFRact+
NSCLC, the subacute and long-term cognitive effects of radiation [12]. For
patients with poor functional status, WBRT has no significant survival or QOL
benefit compared to best supportive care [84••]. Applications of these studies to
the EGFRact+ NSCLC population are limited and there are multiple ongoing
studies evaluating the use of WBRT in combination with TKIs [85]. We reserve
WBRT for patients who have intracranial progression refractory to all systemic
therapies that are not candidates for surgery or SRS, if performance status permits.
Stereotactic radiosurgery
SRS provides high-dose radiation to the target while minimizing exposure to
surrounding normal brain tissue. The number of BrM that can be treated with
SRS is expanding with a recent trial confirming non-inferiority with SRS for up
to 10 metastases compared to WBRT [86]. The use of SRS is limited based on
location and size of lesions as well as degree of vasogenic edema, so that it is
primarily offered to patients with only a few, small BrM (G3 cm given decline in
local control) [87].
Initially, clinical trials evaluated the addition of SRS to WBRT and found
improved survival only for patients with a single BrM, but improved perfor-
mance status of all patients [88]. Subsequent retrospective studies had mixed
findings with some demonstrating improved CNS control however no im-
provement in OS and others actually finding that SRS following WBRT de-
creased survival [89, 90]. Recent post hoc analysis of the EORTC 22952 trial
failed to find a benefit to adjuvant WBRT [91]. Additionally, combination SRS
and WBRT has a significant impact on learning and memory at 4 months
compared to SRS alone [92]. For these reasons, clinical practice has moved
towards the use of SRS alone.
There are multiple hypotheses suggesting that radiation can increase the
efficacy of TKIs possibly by improving BBB penetration or radiosensitizing the
tumors with TKIs [93, 94]. There was a small phase III study that did not find a
survival benefit to up-front SRS compared to conventional chemotherapy; how-
ever, this trial was closed early due to the approval of TKIs [77••]. Phase II and
retrospective studies have supported the use of TKIs as monotherapy to delay
radiation therapy, although these studies were primarily withWBRT ormixture of
radiotherapy (Table 2). Retrospective studies of the use of up-front SRS with TKI
support a survival benefit over the use of TKI monotherapy with salvage radio-
therapy [78••, 95, 96]. A devastating long-term effect of radiation, leukoence-
phalopathy, radiographically presents as diffuse periventricular white matter
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changes [97]. The rate of leukoencephalopathy following SRS is lower thanWBRT
at all time points but is up to 84% at 4 years [98••]. Recognizing the risk of
radiation, at this time, we favor the use of SRS in combination with TKIs for BrM
G3 cm given appropriate performance status.
Management of subacute and late neurologic complications of radiotherapy
Radiation necrosis clinically presents with general and neurologic decline due to
brain edema surrounding a growing necrotic core. In other brain tumor popula-
tions, radiation necrosis has been associated with similar survival as recurrent
disease. Steroids are used as first line management of radiation necrosis. However,
if there is no significant improvement with steroids, we transition to management
with BEV utilizing a standard 6-week protocol [99].
Cognitive impairment can be seen as a result of radiation therapy with
variable reversibility. Acute cognitive complaints within 1 month of radiation
are most commonly related to fatigue or vasogenic cerebral edema and can be
managed conservatively. Cognitive slowing, executive dysfunction, and short-
term memory deficits seen in the 1 to 6 months following radiotherapy may
resolve with time and lifestyle modification. There is limited data that mem-
antine, an NMDA partial antagonist, hyperbaric oxygen and hippocampal
sparing WBRT may prevent this impairment [100–102].
Late cognitive impairment, leukoencephalopathy, increases as a function of
time following both SRS and WBRT [98]. These changes are irreversible and
associated with both demyelinating and cerebrovascular pathology. For these
reasons, it is more common in patients over the age of 70 with vascular disease
or collagen disorders. This has been seen more commonly in WBRT and
clinically is a driving force for delaying WBRT.
Hypopituitarismdevelops in virtually all patients with radiotherapy near the
pituitary and 20% within 5 years. In long-term survivors, monitoring for
pituitary function after radiation therapy is also important.
Emerging therapies
There are multiple ongoing trials as described above to clarify the use of
currently available agents. In addition, for further development of TKIs, the
National LungMatrix Trial is using biomarkers to guide targeted drug therapies.
The use of irinotecan, etoposide, and ATR kinase inhibitors is also under
investigation. When patients progress on TKI and conventional chemotherapy,
we encourage offering additional clinical trials to the patients.
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